دورية أكاديمية
أعرض في EDS

Assessment value of interleukin-6, procalcitonin, and C-reactive protein early kinetics for initial antibiotic efficacy in patients with febrile neutropenia: A prospective study.

التفاصيل البيبلوغرافية
العنوان: Assessment value of interleukin-6, procalcitonin, and C-reactive protein early kinetics for initial antibiotic efficacy in patients with febrile neutropenia: A prospective study.
المؤلفون: Zheng H; Department of Hematology, Central Hospital of Xiangtan, Xiangtan, China., Luo Z; Department of Hematology, Central Hospital of Xiangtan, Xiangtan, China., Yi Y; Department of Hematology, Changsha Central Hospital, Changsha, China., Liu K; Department of Hematology, Central Hospital of Xiangtan, Xiangtan, China., Huo Z; Department of Hematology, Central Hospital of Xiangtan, Xiangtan, China., You Y; Department of Hematology, Central Hospital of Xiangtan, Xiangtan, China., Li H; Department of Hematology, Central Hospital of Xiangtan, Xiangtan, China., Tang M; Department of Hematology, Central Hospital of Xiangtan, Xiangtan, China.
المصدر: Cancer medicine [Cancer Med] 2024 Jul; Vol. 13 (13), pp. e7307.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Malden, MA] : John Wiley & Sons Ltd., c2012-
مواضيع طبية MeSH: C-Reactive Protein*/analysis , C-Reactive Protein*/metabolism , Interleukin-6*/blood , Procalcitonin*/blood , Anti-Bacterial Agents*/therapeutic use , Febrile Neutropenia*/drug therapy , Febrile Neutropenia*/blood , Biomarkers*/blood, Humans ; Male ; Female ; Middle Aged ; Prospective Studies ; Adult ; ROC Curve ; Aged ; Treatment Outcome
مستخلص: Background: This study aims to investigate the early kinetics of interleukin 6 (IL-6), procalcitonin (PCT), and C-reactive protein (CRP) on initial antibiotic efficacy in hematological disorder patients with febrile neutropenia (FN).
Methods: A total of 40 patients with 43 episodes of FN were enrolled and divided into initial antibiotic effective group (IAE group, n = 24) and initial antibiotic ineffective group (IAI group, n = 19). The levels of IL-6, PCT, and CRP before antibacterial treatment (T0), and 12 h (T1), 24 h (T2), 48 h (T3), and 72 h (T4) post-antibacterial treatment were determined, respectively. Furthermore, the receiver operating characteristic curve (ROC) analysis was performed to evaluate the clinical value of indicators.
Results: In IAE group, the IL-6 levels gradually decreased from T0 to T4, and the CRP levels significantly decreased at 48 to 72 h, whereas both IL-6 and CRP remained at high levels in the IAI group. The PCT levels in both groups increased at the early stage of anti-infection (T1-T2) and reached to peak at T1-T2 in effective group. ROC curve analysis identified IL-6 as a predictive biomarker for initial antibiotic efficacy at 12, 48, and 72 h after treatment, with the AUC of 0.698, 0.744, and 0.821, respectively. In addition, CRP demonstrated predictive ability of initial antibiotics against infection at 24, 48, and 72 h after therapy, with the AUC of 0.724, 0.741, and 0.797, respectively. ROC curve analysis of percentage changes demonstrated that IL-6 percentage change showed predictive ability of antibiotic efficacy at the early stage, and both the IL-6 and CRP percentage changes showed the predictive ability of antibiotic efficacy 48 or 72 h after antibiotics therapy.
Conclusion: This study confirmed IL-6 and CRP levels, and the percentage change in IL-6 as the biomarkers for initial antibiotic efficacy prediction in hematological disorder patients with FN.
(© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.)
References: Clin Pharmacol Ther. 2021 Aug;110(2):346-360. (PMID: 33559152)
Infect Drug Resist. 2020 Mar 26;13:903-910. (PMID: 32273735)
Front Immunol. 2021 May 20;12:641879. (PMID: 34093531)
Biomark Med. 2015;9(5):461-71. (PMID: 25985175)
Antimicrob Resist Infect Control. 2020 May 27;9(1):74. (PMID: 32460887)
Support Care Cancer. 2018 Nov;26(11):3819-3826. (PMID: 29777383)
Clin Infect Dis. 2011 Feb 15;52(4):e56-93. (PMID: 21258094)
J Crit Care. 2016 Aug;34:50-5. (PMID: 27288610)
Cytokine. 2019 Apr;116:1-6. (PMID: 30684912)
Support Care Cancer. 2014 Jan;22(1):269-77. (PMID: 24057110)
J Pediatr Hematol Oncol. 2012 Nov;34(8):617-23. (PMID: 22983415)
Transl Pediatr. 2021 Mar;10(3):464-473. (PMID: 33850805)
Leuk Lymphoma. 2019 Oct;60(10):2441-2448. (PMID: 30806111)
Dis Markers. 2020 Jan 23;2020:4873074. (PMID: 32076461)
Clinics (Sao Paulo). 2011;66(10):1699-705. (PMID: 22012040)
Blood Cells Mol Dis. 2021 Sep;90:102586. (PMID: 34126299)
Children (Basel). 2021 Nov 09;8(11):. (PMID: 34828740)
Br J Haematol. 2001 Oct;115(1):53-7. (PMID: 11722409)
Mediators Inflamm. 2017;2017:8291316. (PMID: 28769538)
Ther Adv Infect Dis. 2013 Feb;1(1):37-43. (PMID: 25165543)
Crit Care. 2009;13(2):R38. (PMID: 19291325)
PLoS One. 2011 Apr 25;6(4):e18886. (PMID: 21541027)
Ann Hematol. 2012 Apr;91(4):605-11. (PMID: 21976106)
BMC Infect Dis. 2008 Mar 06;8:28. (PMID: 18321393)
Curr Hematol Malig Rep. 2013 Dec;8(4):370-8. (PMID: 23990311)
Eur J Haematol. 2018 Aug 12;:. (PMID: 30099772)
Hematol Rep. 2014 Jun 23;6(2):5466. (PMID: 25013718)
معلومات مُعتمدة: 2021-xtyx-3 medical research project plan of Xiangtan City in 2021
فهرسة مساهمة: Keywords: C‐reactive protein; febrile neutropenia; initial antibiotic efficacy; interleukin‐6; procalcitonin
المشرفين على المادة: 9007-41-4 (C-Reactive Protein)
0 (Interleukin-6)
0 (Procalcitonin)
0 (Anti-Bacterial Agents)
0 (Biomarkers)
0 (IL6 protein, human)
تواريخ الأحداث: Date Created: 20240705 Date Completed: 20240705 Latest Revision: 20240713
رمز التحديث: 20240713
مُعرف محوري في PubMed: PMC11224913
DOI: 10.1002/cam4.7307
PMID: 38967137
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-7634
DOI:10.1002/cam4.7307